In addition to kidney damage, ketoacidosis and heart attacks, it turns out that canagliflozin – sold under the brand names Invokana and Invokamet – increases the risks of osteoporosis, or loss of bone density.
In addition to kidney damage, ketoacidosis and heart attacks, it turns out that canagliflozin – sold under the brand names Invokana and Invokamet – increases the risks of osteoporosis, or loss of bone density.
Comments for this article are closed.